Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on January 18, 2018. The report discloses a material event under Regulation FD regarding the presentation of clinical trial data for the company's investigational drug, RX-3117.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical development milestones rather than financial performance.
Material Changes and Events
- Clinical Data Presentation: The Company announced that clinical data from the completed Phase IIa trial of RX-3117 in metastatic pancreatic cancer patients will be presented at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 annual meeting.
- Event Details: The poster presentation is scheduled for Friday, January 19, 2018, at 11:30 Pacific Time in San Francisco, California.
- Poster Title: "RX-3117: Activity of an Oral Antimetabolite Nucleoside in Subjects with Pancreatic Cancer – Preliminary Results of Stage II of the Phase Ib/IIa Study."
- Availability: A copy of the poster was made available on the Company's website starting at 12:00 PM Eastern Time on January 19, 2018.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the inherent uncertainties of clinical trial results. The primary focus is the dissemination of preliminary clinical results.
Investor Verification Checklist
- Verify the specific clinical outcomes and safety data presented in the poster at the ASCO GI 2018 meeting.
- Confirm the availability of the poster on the Company's official website.
- Review subsequent press releases or filings for the Company's interpretation of the Phase IIa results and potential next steps for RX-3117 development.
- Note that the registrant name in the filing is Rexahn Pharmaceuticals, Inc., despite the request metadata referencing Opus Genetics, Inc.